{"entity":{"id":"nct06831136","kind":"trial","name":"Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma","aka":["PANCARDINAL-2"],"tldr":"A phase 2 trial in pancreatic cancer, run by The University of Texas Health Science Center, Houston, now recruiting.","summary":"Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma is a phase 2, interventional study registered as NCT06831136 by The University of Texas Health Science Center, Houston, with a registry enrolment figure of 24 participants, started 2025-03-26 and due to reach its primary completion in 2028-01-20. Interventions recorded: Neoadjuvant Chemotherapy (NAC); Immunotherapy (pembrolizumab); Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA). Conditions listed: Pancreatic Ductal Adenocarcinoma. Primary outcome: Efficacy as assessed by the Overall response rate using RECIST v1.1 guidelines. Pancreatic eligibility wording from the registry: \"Patients who have undergone prior resection will be excluded unless there is recurrent pancreatic tumor that is amenable to EUS-RFA\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06831136","url":"https://clinicaltrials.gov/study/NCT06831136"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06831136","phase":"2","setting":"Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma; a Phase II Trial PANcreas CAncer RaDIofrequeNcy AbLation","sponsor":"The University of Texas Health Science Center, Houston","participation":[{"nct":"NCT06831136","source":"https://clinicaltrials.gov/study/NCT06831136","fetchedAt":"2026-10-07T16:55:06.589Z","studySha256":"43302b6932537aeba8f81ec2eb60557bb4b43b30689c37349438826cef5bbfe6","overallStatus":"RECRUITING","lastUpdatePosted":"2025-09-10","leadSponsor":"The University of Texas Health Science Center, Houston","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":24,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["United States"]}],"started":"2025-03-26","startedType":"actual","enrolled":24,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06831136/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}